These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618 [TBL] [Abstract][Full Text] [Related]
25. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Hagan M; Zlotecki R; Medina C; Tercilla O; Rivera I; Wajsman Z; Neulander EZ Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):329-40. PubMed ID: 15145145 [TBL] [Abstract][Full Text] [Related]
26. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. Abugharib A; Jackson WC; Tumati V; Dess RT; Lee JY; Zhao SG; Soliman M; Zumsteg ZS; Mehra R; Feng FY; Morgan TM; Desai N; Spratt DE J Urol; 2017 Mar; 197(3 Pt 1):662-668. PubMed ID: 27614333 [TBL] [Abstract][Full Text] [Related]
27. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. King CR; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668 [TBL] [Abstract][Full Text] [Related]
28. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Gandaglia G; Briganti A; Clarke N; Karnes RJ; Graefen M; Ost P; Zietman AL; Roach M Eur Urol; 2017 Nov; 72(5):689-709. PubMed ID: 28189428 [TBL] [Abstract][Full Text] [Related]
29. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study. Mizowaki T; Aoki M; Nakamura K; Yorozu A; Kokubo M; Karasawa K; Kozuka T; Nakajima N; Sasai K; Akimoto T J Radiat Res; 2015 Jul; 56(4):750-6. PubMed ID: 25910489 [TBL] [Abstract][Full Text] [Related]
30. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions]. Quero L; Mongiat-Artus P; Ravery V; Hennequin V; Maylin C; Desgrandchamps F; Hennequin C Cancer Radiother; 2009 Jul; 13(4):267-75. PubMed ID: 19446487 [TBL] [Abstract][Full Text] [Related]
31. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
32. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Spiotto MT; Hancock SL; King CR Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):54-61. PubMed ID: 17459606 [TBL] [Abstract][Full Text] [Related]
33. Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin : A single center experience. Hegemann NS; Morcinek S; Buchner A; Karl A; Stief C; Knüchel R; Corradini S; Li M; Belka C; Ganswindt U Strahlenther Onkol; 2016 Jul; 192(7):440-8. PubMed ID: 27272660 [TBL] [Abstract][Full Text] [Related]
35. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related]
36. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial. Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850 [TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Patel R; Lepor H; Thiel RP; Taneja SS Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728 [TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667 [TBL] [Abstract][Full Text] [Related]
40. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Do LV; Do TM; Smith R; Parker RG Am J Clin Oncol; 2002 Feb; 25(1):1-8. PubMed ID: 11823687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]